Skip to main content

Advertisement

SpringerLink
Log in

Update on Testosterone Replacement Therapy in Hypogonadal Men

  • Men’s Health (R Carrion and C Yang, Section Editors)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Late-onset male hypogonadism has long been recognized as a treatable medical condition; however, misconceptions about the use of testosterone replacement therapy (TRT) have often led urologists away from its more mainstream use. This paper aims to bring the reader up-to-date on the current understanding of TRT, starting with when and who to treat. Various formulations of TRT, each with its own risks and benefits, are also detailed. Finally, a comprehensive analysis of the current literature’s views into the various controversies of TRT including its impact on prostate health, sexual health, cardiovascular health, frailty, and mood is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31. doi:10.1210/jcem.86.2.7219.

    Article  CAS  PubMed  Google Scholar 

  2. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8(3):639–54. doi:10.1111/j.1743-6109.2010.02200.x. quiz 55.

    Article  CAS  PubMed  Google Scholar 

  3. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87(2):589–98. doi:10.1210/jcem.87.2.8201.

    Article  CAS  PubMed  Google Scholar 

  4. Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010;95(8):3955–64. doi:10.1210/jc.2010-0102.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Corona G, Mannucci E, Ricca V, Lotti F, Boddi V, Bandini E, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl. 2009;32(6):720–8. doi:10.1111/j.1365-2605.2009.00952.x.

    Article  CAS  PubMed  Google Scholar 

  6. McGill JJ, Shoskes DA, Sabanegh ES. Androgen deficiency in older men: indications, advantages, and pitfalls of testosterone replacement therapy. Cleve Clin J Med. 2012;79(11):797–806. doi:10.3949/ccjm.79a.12010.

    Article  PubMed  Google Scholar 

  7. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35. doi:10.1056/NEJMoa0911101.

    Article  CAS  PubMed  Google Scholar 

  8. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011;124(7):578–87. doi:10.1016/j.amjmed.2010.12.027.

    Article  CAS  PubMed  Google Scholar 

  9. Morley JE, Patrick P, Perry 3rd HM. Evaluation of assays available to measure free testosterone. Metabolism. 2002;51(5):554–9.

    Article  CAS  PubMed  Google Scholar 

  10. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol. 2010;73(3):382–8. doi:10.1111/j.1365-2265.2010.03804.x.

    Article  CAS  Google Scholar 

  11. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30(1):1–9. doi:10.2164/jandrol.108.006486.

    Article  PubMed  Google Scholar 

  12. Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920–6. doi:10.1210/jc.2003-031719.

    Article  CAS  PubMed  Google Scholar 

  13. Bhasin S, Basaria S. Diagnosis and treatment of hypogonadism in men. Best Pract Res Clin Endocrinol Metab. 2011;25(2):251–70. doi:10.1016/j.beem.2010.12.002.

    Article  CAS  PubMed  Google Scholar 

  14. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi:10.1210/jc.2009-2354.

    Article  CAS  PubMed  Google Scholar 

  15. Morales A, Bella AJ, Chun S, Lee J, Assimakopoulos P, Bebb R, et al. A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. Can Urol Assoc J. 2010;4(4):269–75.

    PubMed Central  PubMed  Google Scholar 

  16. Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer. 2011;117(17):3953–62. doi:10.1002/cncr.25985.

    Article  PubMed  Google Scholar 

  17. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75. doi:10.1210/jc.2009-2575.

    Article  CAS  PubMed  Google Scholar 

  18. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. 2004;6(3):208–15. doi:10.1111/j.1462-8902.2004.00335.x.

    Article  CAS  PubMed  Google Scholar 

  19. Feneley MR, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med. 2012;9(8):2138–49. doi:10.1111/j.1743-6109.2012.02808.x. Long-term (up to 20 years) TRT with appropriate monitoring shows no increase in the incidence of PCa compared to the general population.

    Article  CAS  PubMed  Google Scholar 

  20. Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009;41(1):7–13. doi:10.1111/j.1439-0272.2008.00880.x.

    Article  CAS  PubMed  Google Scholar 

  21. Zacharin MR, Pua J, Kanumakala S. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism. Clin Endocrinol. 2003;58(6):691–5.

    Article  CAS  Google Scholar 

  22. Hellstrom WJ, Paduch D, Donatucci CF. Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review. Int Urol Nephrol. 2012;44(1):61–70. doi:10.1007/s11255-010-9879-4.

    Article  CAS  PubMed  Google Scholar 

  23. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol. 1994;40(3):341–9.

    Article  CAS  Google Scholar 

  24. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren 3rd R, Murphy GP. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol. 1995;59(4):246–50.

    Article  CAS  PubMed  Google Scholar 

  25. Pearl JA, Berhanu D, Francois N, Masson P, Zargaroff S, Cashy J, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013;190(5):1828–33. doi:10.1016/j.juro.2013.05.111.

    Article  CAS  PubMed  Google Scholar 

  26. Hsueh PR, Graybill JR, Playford EG, Watcharananan SP, Oh MD, Ja’alam K, et al. Consensus statement on the management of invasive candidiasis in intensive care units in the Asia-Pacific region. Int J Antimicrob Ag. 2009;34(3):205–9. doi:10.1016/J.Ijantimicag.2009.03.014.

    Article  CAS  Google Scholar 

  27. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007–19. doi:10.1210/jc.2011-1137.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Haring R, Volzke H, Steveling A, Krebs A, Felix SB, Schofl C, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J. 2010;31(12):1494–501. doi:10.1093/eurheartj/ehq009.

    Article  CAS  PubMed  Google Scholar 

  29. Lin JW, Lee JK, Wu CK, Caffrey JL, Chang MH, Hwang JJ, et al. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med. 2011;8(8):2350–60. doi:10.1111/j.1743-6109.2011.02343.x.

    Article  CAS  PubMed  Google Scholar 

  30. Wehr E, Pilz S, Boehm BO, Grammer TB, Marz W, Obermayer-Pietsch B. Low free testosterone levels are associated with all-cause and cardiovascular mortality in postmenopausal diabetic women. Diabetes Care. 2011;34(8):1771–7. doi:10.2337/dc11-0596.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab. 2013;98(11):4300–10. doi:10.1210/jc.2013-1970.

    Article  CAS  PubMed  Google Scholar 

  32. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97(11):870–5. doi:10.1136/hrt.2010.210757.

    Article  CAS  PubMed  Google Scholar 

  33. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75. doi:10.1210/jc.2007-1792.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol / Eur Fed Endocr Soc. 2011;165(5):687–701. doi:10.1530/EJE-11-0447.

    Article  CAS  Google Scholar 

  35. Svartberg J, von Muhlen D, Mathiesen E, Joakimsen O, Bonaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259(6):576–82. doi:10.1111/j.1365-2796.2006.01637.x.

    Article  CAS  PubMed  Google Scholar 

  36. Tirabassi G, Gioia A, Giovannini L, Boscaro M, Corona G, Carpi A, et al. Testosterone and cardiovascular risk. Intern Emerg Med. 2013;8 Suppl 1:S65–9. doi:10.1007/s11739-013-0914-1.

    Article  PubMed  Google Scholar 

  37. Yeap BB, Hyde Z, Almeida OP, Norman PE, Chubb SA, Jamrozik K, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94(7):2353–9. doi:10.1210/jc.2008-2416.

    Article  CAS  PubMed  Google Scholar 

  38. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21(11):890–4. doi:10.1053/euhj.1999.1873.

    Article  CAS  PubMed  Google Scholar 

  39. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2007;19(2):176–82. doi:10.1038/sj.ijir.3901504.

    Article  CAS  PubMed  Google Scholar 

  40. Phillips GB, Castelli WP, Abbott RD, McNamara PM. Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am J Med. 1983;74(5):863–9.

    Article  CAS  PubMed  Google Scholar 

  41. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737–45. doi:10.1210/jc.2007-1972.

    Article  CAS  PubMed  Google Scholar 

  42. Somani B, Khan S, Donat R. Screening for metabolic syndrome and testosterone deficiency in patients with erectile dysfunction: results from the first UK prospective study. BJU Int. 2010;106(5):688–90. doi:10.1111/j.1464-410X.2009.09145.x.

    Article  PubMed  Google Scholar 

  43. Vikan T, Schirmer H, Njolstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol / Eur Fed Endocr Soc. 2010;162(4):747–54. doi:10.1530/EJE-09-0943.

    Article  CAS  Google Scholar 

  44. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–9. doi:10.1111/j.1742-1241.2006.00992.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33(6):1186–92. doi:10.2337/dc09-1649.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Krasnoff JB, Basaria S, Pencina MJ, Jasuja GK, Vasan RS, Ulloor J, et al. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J Clin Endocrinol Metab. 2010;95(6):2790–9. doi:10.1210/jc.2009-2680.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol, Dial, Transplant: Off Publ Eur Dial Transplant Assoc-Eur Renal Assoc. 2011;26(1):184–90. doi:10.1093/ndt/gfq397.

    Article  CAS  Google Scholar 

  48. Torkler S, Wallaschofski H, Baumeister SE, Volzke H, Dorr M, Felix S, et al. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male: Off J Int Soc Study Aging Male. 2011;14(3):176–82. doi:10.3109/13685538.2010.529194.

    Article  CAS  Google Scholar 

  49. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272–83. doi:10.1111/j.1743-6109.2010.01991.x.

    Article  CAS  PubMed  Google Scholar 

  50. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol / Eur Fed Endocr Soc. 2007;156(5):595–602. doi:10.1530/EJE-06-0737.

    Article  CAS  Google Scholar 

  51. Kaplan SA, Johnson-Levonas AO, Lin J, Shah AK, Meehan AG. Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. Aging Male: Off J Int Soc Study Aging Male. 2010;13(2):108–12. doi:10.3109/13685530903440424.

    Article  CAS  Google Scholar 

  52. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25(2):337–53. doi:10.1016/j.beem.2010.07.002.

    Article  CAS  PubMed  Google Scholar 

  53. Haring R, Teumer A, Volker U, Dorr M, Nauck M, Biffar R, et al. Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality. Andrology. 2013;1(1):17–23. doi:10.1111/j.2047-2927.2012.00002.x.

    Article  CAS  PubMed  Google Scholar 

  54. Saad F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev. 2012;28 Suppl 2:52–9. doi:10.1002/dmrr.2354.

    Article  PubMed  Google Scholar 

  55. Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol. 2006;102(1–5):261–6. doi:10.1016/j.jsbmb.2006.09.032.

    Article  CAS  PubMed  Google Scholar 

  56. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284–93. doi:10.1111/j.1743-6109.2010.01956.x.

    Article  CAS  PubMed  Google Scholar 

  57. Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157(10):681–91. doi:10.7326/0003-4819-157-10-201211200-00004.

    Article  PubMed  Google Scholar 

  58. Raynaud JP, Gardette J, Rollet J, Legros JJ. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int. 2013;111(6):880–90. doi:10.1111/j.1464-410X.2012.11514.x. PSA did not change nor did the incidence of PCa increase significantly while on TRT. It has never been shown that TRT leads to enhanced prostate growth.

    Article  CAS  PubMed  Google Scholar 

  59. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186(3):1005–11. doi:10.1016/j.juro.2011.04.065.

    Article  CAS  PubMed  Google Scholar 

  60. Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int. 2012;110(2):260–5. doi:10.1111/j.1464-410X.2011.10755.x.

    Article  CAS  PubMed  Google Scholar 

  61. Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011;8(7):2079–89. doi:10.1111/j.1743-6109.2011.02265.x.

    Article  CAS  PubMed  Google Scholar 

  62. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310–20. doi:10.1016/j.eururo.2008.09.024.

    Article  PubMed  Google Scholar 

  63. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61. doi:10.1001/jama.296.19.2351.

    Article  CAS  PubMed  Google Scholar 

  64. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009;56(1):48–56. doi:10.1016/j.eururo.2009.03.088.

    Article  CAS  PubMed  Google Scholar 

  65. Atan A, Tuncel A, Yesil S, Balbay D. Serum testosterone level, testosterone replacement treatment, and prostate cancer. Adv Urol. 2013;2013:275945. doi:10.1155/2013/275945.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2000;6(2):132–8. doi:10.4158/EP.6.2.132.

    Article  CAS  Google Scholar 

  67. Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol. 1996;156(2 Pt 1):438–41. discussion 41–2.

    Article  CAS  PubMed  Google Scholar 

  68. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 1994;15(3):212–5.

    CAS  PubMed  Google Scholar 

  69. Endogenous H, Prostate Cancer Collaborative G, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170–83. doi:10.1093/jnci/djm323.

    Article  Google Scholar 

  70. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21(1):9–23. doi:10.1038/ijir.2008.31.

    Article  CAS  PubMed  Google Scholar 

  71. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A: Biol Med Sci. 2005;60(11):1451–7.

    Article  Google Scholar 

  72. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila Jr D, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–60. doi:10.1016/j.juro.2010.11.084.

    Article  CAS  PubMed  Google Scholar 

  73. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2. doi:10.1097/01.ju.0000136269.10161.32.

    Article  CAS  PubMed  Google Scholar 

  74. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6(4):1165–70. doi:10.1111/j.1743-6109.2009.01161.x.

    Article  CAS  PubMed  Google Scholar 

  75. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–44. doi:10.1016/j.juro.2013.02.002.

    Article  CAS  PubMed  Google Scholar 

  76. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536–41. doi:10.1002/cncr.22438.

    Article  CAS  PubMed  Google Scholar 

  77. Khera M. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009;6 Suppl 3:234–8. doi:10.1111/j.1743-6109.2008.01159.x.

    Article  PubMed  Google Scholar 

  78. Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, de Ronde W. Guidelines on male hypogonadism. European Association of Urology 2014. http://www.uroweb.org/guidelines/online-guidelines/.

  79. Food and Drug Administration. Joint meeting of the Bone, Reproductive and Urologic Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM418144.pdf. TRT’s effect on CVD safety is not well understood and warrants further investigation.

  80. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6 Pt 1):528–40. doi:10.1111/j.1365-2605.2010.01117.x.

    Article  CAS  PubMed  Google Scholar 

  81. Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994;43(2):212–9.

    Article  CAS  PubMed  Google Scholar 

  82. Haffner SM, Mykkanen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab. 1993;77(6):1610–5. doi:10.1210/jcem.77.6.8263149.

    CAS  PubMed  Google Scholar 

  83. Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda GP, et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab. 2006;91(1):345–7. doi:10.1210/jc.2005-1097.

    Article  CAS  PubMed  Google Scholar 

  84. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90(8):871–6. doi:10.1136/hrt.2003.021121.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  85. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–8. doi:10.1210/jc.2003-031069.

    Article  CAS  PubMed  Google Scholar 

  86. Hall J, Jones RD, Jones TH, Channer KS, Peers C. Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology. 2006;147(6):2675–80. doi:10.1210/en.2005-1243.

    Article  CAS  PubMed  Google Scholar 

  87. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Investig. 2011;34(7):557–67. doi:10.3275/7806.

    CAS  Google Scholar 

  88. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–37. doi:10.2337/dc10-1233. TRT improved the risk factors for cardiovascular health including lipid profiles, insulin resistance, lipoprotein A levels, as well as improving sexual health.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. He J, Bhasin S, Binder EF, Yarasheski KE, Castaneda-Sceppa C, Schroeder ET, et al. Cardiometabolic risks during anabolic hormone supplementation in older men. Obesity. 2013;21(5):968–75. doi:10.1002/oby.20081.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  90. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22. doi:10.1056/NEJMoa1000485.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Vigen R, O’Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36. doi:10.1001/jama.2013.280386.

    Article  CAS  PubMed  Google Scholar 

  92. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi:10.1371/journal.pone.0085805.

    Article  PubMed Central  PubMed  Google Scholar 

  93. NCT01377103 trial. https://clinicaltrials.gov/ct2/show/NCT01377103?term=NCT01377103&rank=1.

  94. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63(3):280–93. doi:10.1111/j.1365-2265.2005.02339.x.

    Article  CAS  Google Scholar 

  95. Aversa A, Bruzziches R, Francomano D, Greco EA, Fornari R, Di Luigi L, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male: Off J Int Soc Study Aging Male. 2012;15(2):96–102. doi:10.3109/13685538.2011.631230.

    Article  CAS  Google Scholar 

  96. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414–24. doi:10.1038/nrendo.2013.73.

    Article  CAS  PubMed  Google Scholar 

  97. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283(1):E154–64. doi:10.1152/ajpendo.00502.2001.

    Article  CAS  PubMed  Google Scholar 

  98. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab. 2006;91(8):3024–33. doi:10.1210/jc.2006-0357.

    Article  CAS  PubMed  Google Scholar 

  99. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab. 2003;285(1):E197–205. doi:10.1152/ajpendo.00370.2002.

    Article  CAS  PubMed  Google Scholar 

  100. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289–305. doi:10.1097/01.pra.0000358315.88931.fc.

    Article  PubMed  Google Scholar 

  101. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry. 2009;70(7):1009–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Kevin Matthew Yen Bing Leung and Khalid Alrabeeah each declare no potential conflicts of interest. Serge Carrier is an advisory board member (Astellas, Eli Lilly Canada, Pfizer Canada, Bayer Canada, Abbott, Novartis, Actavis), has received honoraria for speaking at symposia and lectures (Eli Lilly Canada, Pfizer Canada, Abbott, Actavis, Merk), and has received research grants and clinical trial support (Astellas, Eli Lilly Canada, Pfizer Canada).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. McGill University, 9D-1210 Boulevard de Maisonneuve Ouest, Montreal, QC, H3A0A2, Canada

    Kevin Matthew Yen Bing Leung

  2. Infertility and Andrology, Urology, McGill University, Montréal, Québec, Canada

    Khalid Alrabeeah

  3. Urology Division, McGill University, Montréal, Québec, Canada

    Serge Carrier

  4. McGill University Heatlh Centre - Glen Site, Room 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, Canada

    Kevin Matthew Yen Bing Leung

Authors
  1. Kevin Matthew Yen Bing Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khalid Alrabeeah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serge Carrier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin Matthew Yen Bing Leung.

Additional information

This article is part of the Topical Collection on Men’s Health

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leung, K.M.Y.B., Alrabeeah, K. & Carrier, S. Update on Testosterone Replacement Therapy in Hypogonadal Men. Curr Urol Rep 16, 57 (2015). https://doi.org/10.1007/s11934-015-0523-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-015-0523-9

Keywords

Search

Navigation